Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen astraZeneca Collaboration — Net SG&A Cost Recovery (Expense) ($M) ($M)
Form 10-K Note 3 Collaborations (XBRL)
Latest, FY2023
73
Period ended Dec 31, 2023
Change on a year earlier
+21.7%
60 in FY2022
History
4 years
Since FY2020
Sources
2
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | AstraZeneca Collaboration — Net SG&A Cost Recovery (Expense) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 73 | +21.7% | Form 10-K (filed 2024-02-14) ↗ |
| FY2022 | Dec 31, 2022 | 60 | +53.8% | Form 10-K (filed 2024-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 39 | +143.8% | Form 10-K (filed 2024-02-14) ↗ |
| FY2020 | Dec 31, 2020 | 16 | – | Form 10-K (filed 2023-02-09) ↗ |
Cite this data
StockData. (2026). Amgen AstraZeneca Collaboration — Net SG&A Cost Recovery (Expense) ($M) ($M), annual FY2020–FY2023 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/collab_az_sga
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.